Tag Archives: CytomX

October, 2017

4 October
Amgen and CytomX Enter Immuno-Oncology Collaboration

THOUSAND OAKS, Calif. and SOUTH SAN FRANCISCO, Calif., Oct. 3, 2017 /PRNewswire/ — Amgen (NASDAQ: AMGN) and CytomX Therapeutics, Inc., (NASDAQ: CTMX) today announced that the companies have entered into a strategic collaboration in immuno-oncology. The companies will co-develop a CytomX Probody™ T-cell engaging bispecific against the Epidermal Growth Factor …
Share

20 March
Bristol-Myers and CytomX Expand Collaboration to Discover Probody Therapeutics for Treatment of Cancer and Other Diseases

NEW YORK & SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Bristol-Myers Squibb Company (NYSE:BMY) and CytomX Therapeutics, Inc. (Nasdaq:CTMX), a biopharmaceutical company developing investigational Probody therapeutics for the treatment of cancer, today announced an expansion of their 2014 strategic collaboration to discover novel therapies that will include up to eight additional targets …
Share

22 April
AbbVie and CytomX Announce Collaboration for Probody Drug Conjugates

NORTH CHICAGO, Ill. and SOUTH SAN FRANCISCO, Calif., April 21, 2016 /PRNewswire/ — AbbVie (NYSE: ABBV) and CytomX Therapeutics, Inc. (Nasdaq: CTMX) today announced that they have entered into a collaboration to co-develop and co-commercialize Probody™ Drug Conjugates against CD71, also known as transferrin receptor 1 (TfR1). CD71 is highly …
Share